Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Pharmaceuticals Inc.

http://www.auriniapharma.com/

Latest From Aurinia Pharmaceuticals Inc.

Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

GSK's Eyes Benlysta Expansion With First US FDA Lupus Nephritis Approval

The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.

Immune Disorders Approvals

US FDA’s Vaccine Advisory Committee Roster Tweaked For Moderna Review

After the various turnovers, the panel will be one person smaller, and while the agenda includes familiar topics, including maintaining placebo controls after a vaccine is available, the presentation order will be different.

Advisory Committees Vaccines

Artios Pharma Nears Clinic With DNA Repair Response Anticancers

The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.

Cancer Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alberta Ltd.
    • Isotechnika Pharma Inc.
UsernamePublicRestriction

Register